Alterity Therapeutics Says Treatment With ATH434 Neuroprotective And Improved Motor Function

Alterity Therapeutics (ATHE) said a preclinical study showed that treatment with ATH434 was neuroprotective and improved motor function. Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces a-synuclein related neurodegeneration in a widely accepted murine model of Multiple System Atrophy or MSA.

By targeting a-synuclein and excess brain iron in MSA, Alterity believes that ATH434 can treat the underlying cause of the devastating disease which has no approved therapy.

The company said it remains on track to initiate its phase 2 clinical trial of ATH434 in patients with MSA by the end of the calendar year.

The preclinical study showed that treatment with ATH434 was neuroprotective and improved motor function, independently confirming and extending previous findings from another academic laboratory, both in the same MSA model as well as animal models of Parkinson's Disease.

In preserving neurons, ATH434 reduced both the aggregated form of a-synuclein and the so-called toxic oligomeric form, which is thought to underlie the spreading of disease to other neurons.

At the same time, ATH434 significantly reduced brain iron in areas of pathology, consistent with its mechanism of action.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT